ABCAM Plc Notice of Interim Results (6577E)

TIDMABC

RNS Number : 6577E

ABCAM Plc

11 February 2015

 
 For immediate release   11 February 
                                2015 
 

ABCAM PLC

("Abcam" or "the Company")

Notification of Interim Results

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, will announce its interim results for the six months ended 31 December 2014 on Monday 9 March 2015.

A briefing for analysts will be held at 0930 (UK time) on 9 March at the offices of Brunswick Group LLP, 16 Lincoln's Inn Fields, London, WC2A 3ED.

A live audio webcast and slide presentation of this event will be available at www.abcamplc.com, for which we recommend you register by 0915 (UK time). There will also be a conference call dial-in available - details will be provided in the announcement of interim results at 0700 on 9 March.

For further information please contact:

 
                                                             + 44 (0) 1223 
Abcam                                                              696 000 
Jeff Iliffe, Chief Financial Officer 
 Laura Taylor, Investor Relations Manager 
J.P.Morgan Cazenove - Nominated Adviser & Joint           + 44 (0) 20 7742 
 Corporate Broker                                                     4000 
James Mitford / Alex Bruce - Nominated Adviser 
 
                                                          + 44 (0) 20 7418 
Peel Hunt LLP - Joint Corporate Broker                                8900 
Clare Terlouw / Jock Maxwell MacDonald - Corporate 
 Broking 
                                                           [phone] 
Brunswick                                                             5959 
Justine Mcllroy / Will Medvei / Anna Carruth 
 
 
 

Notes to Editors

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLLFLSFAILLIE